Roche announces implementation plans for its Operational Excellence Program
- Details
- Category: Roche
Roche disclosed the measures it plans to take as part of its Group-wide Operational Excellence Program, announced in September. The initiative is a response to mounting cost pressures in healthcare - particularly in the US and Europe - and to increasing hurdles for the approval and pricing of new medicines.
Boehringer Ingelheim steps up to the challenge in support of World Diabetes Day
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim employees across the globe were called to action in support of this year's World Diabetes Day. Equipped with pedometers for a week, each step taken by employees was counted and converted into a contribution of 15.000 Euros in support of the International Diabetes Federation's (IDF) "Life for a Child" Programme.
Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced results from the EMPHASIS-HF trial(1) showing a statistically significant reduction in risk of cardiovascular (CV) death or heart failure (HF) hospitalization for patients with chronic heart failure with mild symptoms treated with Inspra® (eplerenone) versus those given placebo in addition to standard HF therapy.
Rivaroxaban Significantly Reduces Risk of Stroke with Comparable Safety versus Warfarin
- Details
- Category: Bayer
Bayer announced the results from the pivotal, double-blind Phase III, ROCKET AF trial. In the study, rivaroxaban demonstrated superiority to warfarin in reducing the risk of stroke and non-CNS systemic embolism in patients with atrial fibrillation (AF).
Diabetes awareness survey reveals alarming figures across the Middle East and Northern Africa regions
- Details
- Category: Novo Nordisk
In the lead up to World Diabetes Day 2010 on 14 November Novo Nordisk and Ipsos Emirates Health conducted a survey in ten countries of the Middle East and Northern Africa (MENA) region: Algeria, Egypt, Iran, Iraq, Jordan, Lebanon, Morocco, Kingdom of Saudi Arabia (KSA), Tunisia and the United Arab Emirates (UAE).
Collaboration of Boehringer Ingelheim and VTU Technology
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim, a global leader in biopharmaceutical contract development and manufacture, and VTU Technology, a leading supplier of exclusive technologies and comprehensive services for the development of high-performance Pichia pastoris protein expression strains, have entered into a global Technology and Marketing collaboration agreement.
Bristol-Myers Squibb Foundation Launches $100 Million Initiative Targeting America's Type 2 Diabetes Crisis
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb Foundation announced Together on Diabetes®: Communities Uniting to Meet America's Diabetes Challenge, a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor's office - in their homes and communities - and for the course of their disease.
More Pharma News ...
- Nycomed is keeping the pace in third quarter 2010
- Alpine Mountaineer and Alzheimer's Advocate to Climb Highest Peak on Each Continent
- Roche reports promising Phase II results with new targeted approach in advanced melanoma
- Genzyme Responds to Sanofi-Aventis Letter
- Sanofi-aventis Sends Letter to Genzyme Seeking Clarification on Potential Board Actions
- Abbott Remains on the Dow Jones Sustainability Indexes for the Sixth Consecutive Year
- Bayer raises its brand profile